FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Check this box if no longer subject
o Section 16. Form 4 or Form 5
obligations may continue. See
notruction 1(h)

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

					or Se	ectio	on 30(ł	n) of t	thè Í	nvestm	ent C	ompany Act o	f 1940								
								Issuer Name and Ticker or Trading Symbol [OOKIPA Pharma Inc. [HOOK]								all app	tor	•	X 10% O	wner	
(Last) (First) (Middle) C/O HOOKIPA PHARMA INC., 350						3. Date of Earliest Transaction (Month/Day/Year) 03/22/2021										Office below	er (give title		Other (below)	(specify	
FIFTH, AVENUE, 72ND FLOOR, SUITE 7240							4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable					
(Street) NEW YORK NY 10118															Form filed by One Reporting Person X Form filed by More than One Reporting Person						
(City)	(S	tate) (2	Zip)																		
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																					
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Yell)						Execu (ear) if any		eemed ution Date, / th/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Disposed Of	Acquired (A) o (D) (Instr. 3, 4 a		or and 5)	5. Amo Securi Benefi Owned	ties cially I Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership	
									Ī	Code	v	Amount	(A) or (D)	Price		Transa	iction(s) 3 and 4)	.		(Instr. 4)	
Common Stock 03/22/2021							1			S ⁽¹⁾		40,534	D	\$14	.5375	3,6	599,430		D ⁽²⁾		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned																					
	(e.g., puts, calls, warrants, options, convertible securit														-						
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execu	eemed ution Date, th/Day/Year)	4. Transactic Code (Inst 8)				tive ties ed sed	Expiration D			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		Der Sed (Ins	Price of rivative curity str. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ow For Dir or (I)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A	s) ((D)	Date Exerc	isable	Expiration Date	Title	Amou or Numb of Share	er						
1. Name and Address of Reporting Person* SOFINNOVA CAPITAL VI FCPR																					
(Last) (First) (Middle) C/O HOOKIPA PHARMA INC., 350 FIFTH, AVENUE, 72ND FLOOR, SUITE 7240																					
(Street) NEW YORK NY 10118																					
(City)		(State)	(7	'in)																	

Explanation of Responses:

(Last)

(Street) **NEW YORK**

(City)

1. Name and Address of Reporting Person^* Sofinnova Partners SAS

C/O HOOKIPA PHARMA INC., 350

(First)

FIFTH AVENUE, 72ND FLOOR, SUITE 7240

NY

(State)

1. Shares sold pursuant to a Rule 10b5-1 trading plan dated September 30, 2020 previously adopted by the Reporting Person.

(Middle)

10118

(Zip)

2. Sofinnova Partners SAS is the managing company of Sofinnova Capital VI FCPR and disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any.

/s/ Monique Saulnier, Name: Monique Saulnier, Title: Managing Partner of Sofinnova Partners SAS

03/24/2021

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.